We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00790218
Recruitment Status : Completed
First Posted : November 13, 2008
Results First Posted : February 27, 2015
Last Update Posted : May 17, 2022
Information provided by (Responsible Party):
Can-Fite BioPharma

Brief Summary:
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: CF102 Phase 1 Phase 2

Detailed Description:
This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in 2 phases: a dose-escalation phase, to determine the MTD of CF102 and to evaluate its safety/tolerability, PK, pharmacodynamic, and preliminary clinical activity; and a dose-confirmation phase, which will be a cohort expansion at or below the MTD (ie, the RP2D) of CF102. Subjects will be treated with oral doses of CF102 in consecutive, 28-day cycles. The initial dose of CF102 will be 1 mg twice daily (BID), with subsequent escalations to 5 and 25 mg BID, unless limited by toxicity. Subjects will be evaluated weekly for the first cycle, every 2 weeks for Cycles 2 and 3, and at the end of each subsequent cycle, up to 6 cycles of CF102 treatment. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Study Arms: CF102 (1, 5, and 25 mg BID) in 28-day cycles.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma
Actual Study Start Date : February 2009
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: CF102 1mg
An open-label trial in 28-day cycles.
Drug: CF102
CF102 capsules twice daily by mouth
Other Names:
  • 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide
  • Cl-IB-MECA

Experimental: CF102 5mg
An open-label trial in 28-day cycles.
Drug: CF102
CF102 capsules twice daily by mouth
Other Names:
  • 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide
  • Cl-IB-MECA

Experimental: CF102 25mg
An open-label trial in 28-day cycles.
Drug: CF102
CF102 capsules twice daily by mouth
Other Names:
  • 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide
  • Cl-IB-MECA

Primary Outcome Measures :
  1. Dose Limiting Toxicity [ Time Frame: From start of treatment until Day 28 of Cycle 1 ]
    Dose-limiting toxicity was defined as a clinically significant AE or laboratory abnormality occurring in Cycle 1

  2. Maximum Tolerated Dose [ Time Frame: first 28 days (Cycle 1) ]
    The MTD was defined as the highest dose level at which < 2 of 6 patients developed Cycle 1 DLT.

  3. Maximum Plasma Concentration of CF102 (Cmax) [ Time Frame: Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose ]
    Blood samples were collected and plasma concentrations determined using a high-pressure liquid chromatography method.

Secondary Outcome Measures :
  1. Number of Subjects With Objective Tumor Response [ Time Frame: 6 months ]
    Therapeutic effect of CF102 in hepatocellular carcinoma measured by number of subjects with objective tumor response

  2. Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102 [ Time Frame: Baseline to Day 28 ]
    The Peripheral Blood Mononuclear Cells (PBMC) were to be collected at Baseline and Day 28 in order to evaluate the Adenosine A3 receptor (A3AR) and PBMC biomarkers, and clinical effects of CF102.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of HCC:

    • For patients without underlying cirrhosis, diagnosis of HCC documented by cytology and/or histology
    • For patients with underlying cirrhosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Appendix V).
  2. HCC is advanced, refractory, or metastatic, and no standard therapies are expected to be curative.
  3. At least 18 years of age.
  4. For subjects in the dose-confirmation (RP2D) phase only: Measurable disease, using Response Evaluation Criteria in Solid Tumors (RECIST, Appendix IV). (Note that a lesion that has been subjected to radiotherapy or chemoembolization cannot be used as a target lesion.)
  5. Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at baseline.
  6. The following laboratory values must be documented within 3 days prior to initiation of study drug:

    • Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L
    • Platelet count greater than or equal to 50 x 109/L
    • Serum creatinine less than or equal to 2.0 mg/dL
    • Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal.
    • Total bilirubin ≤ 3.0 mg/dL.
    • Serum albumin ≥ 3.0 g/dL.
    • International normalized ratio (INR) ≤ 2.3.
  7. Esophageal bleeding and varices, if present, have been sclerosed or banded, and no bleeding episodes have occurred during the prior 6 months.
  8. Life expectancy of ≥ 12 weeks.
  9. For women of childbearing potential, negative serum pregnancy test result.
  10. Absence of active malignancy other than HCC within 2 years of entry, with the exception of basal cell carcinoma and squamous cell carcinoma of the skin.
  11. Provide written informed consent to participate.
  12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study related procedures.


Exclusion Criteria:

  1. Any chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, corticosteroids > 20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.
  2. Major surgery or radiation therapy within 28 days prior to initiation of study drug.
  3. Severe liver dysfunction (Child-Pugh Class C or hepatic encephalopathy).
  4. Active infection requiring systemic therapy.
  5. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
  6. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to > 450 msec for males or > 470 msec for females.
  7. Pregnant or lactating female.
  8. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator (PI), are effective and adequate for that patient's circumstances while on study drug.
  9. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug.
  10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
  11. Any severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00790218

Layout table for location information
Rabin Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Can-Fite BioPharma
Layout table for investigator information
Study Director: Michael H Silverman, MD Can-Fite BioPharma Ltd
Principal Investigator: Salomon Shtemmer, MD Rabin Medical Center
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Can-Fite BioPharma
ClinicalTrials.gov Identifier: NCT00790218    
Other Study ID Numbers: CF102-102HCC
First Posted: November 13, 2008    Key Record Dates
Results First Posted: February 27, 2015
Last Update Posted: May 17, 2022
Last Verified: April 2022
Keywords provided by Can-Fite BioPharma:
Hepatocellular carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action